@LongTony, I think the price benchmarking risk is mitigated with the new formulation. IV formulation is far more convenient in terms of dosing for the patient and medical staff. It also avoids hospital burden (especially pertinent in the US - $$$) which is better for insurers, too.
I was debating licensing old Zan with @IndexInvestor when the new formulation was announced - https://hotcopper.com.au/threads/ann-race-develops-improved-iv-formulation-of-zantrene.6983308/
I still think this is the way to go.
Ann: Quarterly Activity Report & Appendix 4C, page-46
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
